LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in LAVA Therapeutics NV as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −6 vs. Q1 2021
- Shares held
- 8.77M
- −449.9K (−4.9%) vs. Q1 2021
- Total value
- $95.5M
- −$43.6M (−31.4%) vs. Q1 2021
- New holders
- 4
- 4 more added
- Sold out
- 10
- 7 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,327,312 | $36.2M | 1.61% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,816,196 | $30.6M | 0.45% | −8,213−0.3% | Reduced |
| Nicholas Investment Partners, LP | 781,867 | $8.51M | 0.53% | −32,973−4.0% | Reduced |
| Nantahala Capital Management, LLC | 381,227 | $4.15M | 0.23% | 00.0% | Unchanged |
| AXA S.A. | 220,663 | $2.40M | 0.01% | +300+0.1% | Added |
| Sphera Funds Management Ltd. | 215,359 | $2.34M | 0.22% | +1,465+0.7% | Added |
| Wellington Management Group LLP | 203,800 | $2.22M | 0.00% | +58,400+40.2% | Added |
| Artal Group S.A. | 200,000 | $2.18M | 0.05% | 00.0% | Unchanged |
| Falcon Edge Capital, LP | 144,902 | $1.58M | 0.10% | −5,552−3.7% | Reduced |
| Millennium Management LLC | 138,831 | $1.51M | 0.00% | −87,374−38.6% | Reduced |
| DAFNA Capital Management LLC | 135,632 | $1.48M | 0.31% | +135,632 | New |
| Woodline Partners LP | 86,904 | $946.0K | 0.02% | −26,338−23.3% | Reduced |
| Citadel Advisors LLC | 61,874 | $674.0K | 0.00% | +1,432+2.4% | Added |
| Bank of New York Mellon Corp | 25,288 | $275.0K | 0.00% | −9,031−26.3% | Reduced |
| New York State Common Retirement Fund | 19,136 | $208.0K | 0.00% | −6,836−26.3% | Reduced |
| Geode Capital Management, LLC | 12,997 | $141.0K | 0.00% | +12,997 | New |
| Tower Research Capital LLC (TRC) | 557 | $6.00K | 0.00% | +557 | New |
| TSFG, LLC | 400 | $4.00K | 0.00% | +400 | New |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −265,000−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −56,010−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −54,000−100.0% | Sold out |
| Caas Capital Management LP | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −25,900−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −19,614−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −17,300−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −9,355−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −5,561−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |